BIOLIFE SOLUTIONS INC 8K

BioLife Solutions reported strong Q2 2026 results and announced a definitive agreement to be acquired by Repligen in a ~$1.5 billion cash-and-stock transaction expected to close in Q4 2026, after which BioLife will no longer be publicly traded.

On August 6, 2026, BioLife Solutions, Inc. reported its financial results for the quarter and six months ended June 30, 2026, highlighting a 21% year-over-year increase in second quarter revenue to $28.5 million, GAAP gross margin of 64% (65% non-GAAP), GAAP net income of $45.1 million driven largely by a $42.4 million non-cash income tax benefit from the release of a valuation allowance, and non-GAAP adjusted EBITDA of $7.4 million (26% of revenue); the company also disclosed that on July 21, 2026 it entered into a definitive agreement to be acquired by Repligen Corporation in a cash-and-stock transaction valuing BioLife at approximately $1.5 billion, under which BioLife shareholders will receive $11.25 in cash and 0.1442 Repligen shares per BioLife share, and that BioLife will cease to be publicly traded upon the expected closing of the merger in the fourth quarter of 2026, subject to shareholder and regulatory approvals and other customary conditions.

Filing Facts

CIK

834365

Ticker

-

Form

8K

Source Type

sec

Accession

0001628280-26-054288

Alert Tier

8